Efficacy of chemotherapy after progression with nivolumab in squamous cell carcinoma of the head and neck

被引：7

作者：

Suzuki, Shinsuke ^{[1
]}

Toyoma, Satoshi ^{[1
]}

Tomizawa, Hiroki ^{[1
]}

Yamada, Toshiki ^{[1
]}

Iikawa, Nobuko ^{[1
]}

Shiina, Kazuhiro ^{[1
]}

Saito, Hidekazu ^{[1
]}

Koizumi, Koh ^{[1
]}

Kawasaki, Yohei ^{[1
]}

Yamada, Takechiyo ^{[1
]}

机构：

[1] Akita Univ, Dept Otorhinolaryngol & Head & Neck Surg, Grad Sch Med, Akita 0108543, Japan

来源：

AURIS NASUS LARYNX | 2020年 / 47卷 / 03期

关键词：

Head and neck squamous cell carcinoma; Immune checkpoint inhibitor; Nivolumab; Chemotherapy; Recurrence; Metastasis; INVESTIGATORS CHOICE; RESPONSE RATES; RECURRENT; INHIBITORS; CETUXIMAB; THERAPY; CANCER; TRIAL;

D O I：

10.1016/j.anl.2019.06.004

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

Nivolumab, a programmed death-1 (PD-1) inhibitor, has shown promising results against squamous cell carcinoma of the head and neck (SCCHN) in cases of recurrence or in a metastatic setting after platinum-based therapy. However, treatment alternatives for patients with nivolumab-refractory are limited, and a constant opinion is not provided. Recently, accumulating studies have demonstrated that chemotherapy after immune checkpoint inhibitor treatment may induce better objective responses in patients with advanced non-small cell lung cancer. However, there are few reports on the increased effect of chemotherapy after nivolumab treatment in SCCHN. Therefore, cases must be accumulated to identify patients with nivolumab-refractory SCCHN who may benefit from chemotherapy. Here, we present patients with SCCHN who exhibited a significant response to chemotherapy after nivolumab treatment. (C) 2019 Elsevier B.V. All rights reserved.

引用

页码：485 / 488

页数：4

共 50 条

[41] Nivolumab for Squamous-Cell Cancer of Head and Neck
Bins, Sander
van Meerten, Esther
Mathijssen, Ron H. J.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (06): : 595 - 596
[42] CHEMOTHERAPY FOR PALLIATION IN SQUAMOUS CARCINOMA OF THE HEAD AND NECK
MORTON, RP
CAMPBELL, I
STELL, PM
[J]. CLINICAL OTOLARYNGOLOGY, 1983, 8 (05): : 363 - 363
[43] New Candidate Markers of Head and Neck Squamous Cell Carcinoma Progression
Kakurina, G. V.
Kolegova, E. S.
Cheremisina, O. V.
Kulbakin, D. E.
Choinzonov, E. L.
[J]. PHYSICS OF CANCER: INTERDISCIPLINARY PROBLEMS AND CLINICAL APPLICATIONS (PC IPCA), 2017, 1882
[44] Epigenetic events of disease progression in head and neck squamous cell carcinoma
Worsham, Maria J.
Chen, Kang Mei
Meduri, Venkata
Nygren, Anders O. H.
Errami, Abdellatif
Schouten, Jan P.
Benninger, Michael S.
[J]. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2006, 132 (06) : 668 - 677
[45] Prognosis after salvage chemotherapy for locally unresectable recurrent squamous cell carcinoma of the head and neck
Kohno, N
Kitahara, S
Kawaida, M
Ohmuma, T
[J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1999, 29 (10) : 462 - 466
[46] Consolidative Chemotherapy in Head & Neck Squamous Cell Carcinoma With Residual Disease After Definitive Chemoradiation
Chureemas, Teeranuch
Juengsamarn, Jitlada
Jiarpinitnun, Chuleeporn
Layangkool, Thanit
Chansriwong, Phichai
Pattaranutaporn, Poompis
Ngamphaiboon, Nuttapong
[J]. ANNALS OF ONCOLOGY, 2016, 27
[47] Chemotherapy postimmunotherapy for recurrent metastatic head and neck squamous cell carcinoma
Ducoulombier, Agnes
Guigay, Joel
Etienne-Grimaldi, Marie-Christine
Saada-Bouzid, Esma
[J]. CURRENT OPINION IN ONCOLOGY, 2023, 35 (03) : 166 - 177
[48] COMBINATION CHEMOTHERAPY FOR ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
PERRY, D
WELTZ, M
BROWN, A
BERENBERG, J
[J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 530 - 530
[49] Radiotherapy and chemotherapy in locally advanced head and neck squamous cell carcinoma
Krstevska, V.
[J]. JOURNAL OF BUON, 2009, 14 (03): : 361 - 373
[50] EXPERIENCE WITH CHEMOTHERAPY AND HYALURONIDASE IN SQUAMOUS-CELL CARCINOMA OF HEAD AND NECK
NEUMANN, H
BAUMGARTNER, G
[J]. WIENER KLINISCHE WOCHENSCHRIFT, 1988, 100 (24) : 14 - 14

← 1 2 3 4 5 →